Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 3/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.49 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BLM | P54132 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6372116 | 1.00 | ADRA1A (0.54) | ADRA1AADRA2AHSD17B10LMNACYP1A2 | |
| SCHEMBL6372120 | 1.00 | ADRA1A (0.54) | ADRA1AADRA2AHSD17B10LMNACYP1A2 | |
| SCHEMBL5368219 | 0.86 | ADRA1A (0.65) | ADRA1AADRA2AHSD17B10LMNACYP1A2 | |
| SCHEMBL7604678 | 0.84 | AKR1C2 (0.49) | ADRA1AADRA2AHSD17B10CYP1A2TSHR | |
| SCHEMBL7604681 | 0.84 | AKR1C2 (0.49) | ADRA1AADRA2AHSD17B10CYP1A2TSHR | |
| SCHEMBL7604674 | 0.84 | AKR1C2 (0.49) | ADRA1AADRA2AHSD17B10CYP1A2TSHR | |
| SCHEMBL7354012 | 0.84 | ADRA1A (0.50) | ADRA1AADRA2AHSD17B10LMNACYP1A2 | |
| SCHEMBL7354017 | 0.84 | ADRA1A (0.50) | ADRA1AADRA2AHSD17B10LMNACYP1A2 | |
| SCHEMBL24977468 | 0.80 | POLB (0.53) | LMNACYP1A2PTGS1KMT2AHTT | |
| SCHEMBL27436626 | 0.80 | POLB (0.53) | LMNACYP1A2PTGS1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838478-B2 | Amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2005-01-04 | — | — | US | disclosed |
| EP-0910573-B1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2003-01-29 | — | — | EP | disclosed |
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-14 | — | — | US | disclosed |
| US-6255301-B1 | CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS | ASTRAZENECA AB (SE) | 2001-07-03 | — | — | US | disclosed |
| EP-0910573-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | Astra Aktiebolag (SE) | 1999-04-28 | — | — | EP | disclosed |
| WO-1997046577-A1 | NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1997-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019371-A1 | New amino acid derivatives and their use as thrombin inhibitors | F2, SERPINC1, FGB | ADRA1A 2845/4885ADRA2A 3665/4885HSD17B10 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.